Stem cell-based products for veterinary use: specific questions on sterility to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) - Scientific guideline
Table of contents
The guidance, in the form of questions and answers, addresses concerns raised by manufacturers and authorities regarding the sterility (absence of bacteria, fungi and mycoplasma) of allogenic stem cell therapies in the veterinary sector. Allogenic stem cell-based veterinary medicines originate from tissues (such as bone marrow or fat) from a donor from the same species of animal, not from the recipient of the cells. These products are manufactured in large batches which need to be sterile as they are administered by injection directly into the body. The guidance was developed following a review of scientific information in relation to stem cell products intended for veterinary use.
Keywords: Stem cell, veterinary, microbiological control, manufacture, good manufacturing practice (GMP)
-
List item
Questions and Answers on allogenic stem cell-based products for veterinary use: specific questions on sterility (PDF/120.49 KB)
Adopted
First published: 23/06/2017
Last updated: 23/06/2017
EMA/CVMP/ADVENT/751229/2016 -
List item
Stem cell-based products for veterinary use: specific questions on sterility to be addressed by ADVENT - draft (PDF/83.89 KB)
Draft: consultation closed
First published: 04/03/2016
Last updated: 04/03/2016
Consultation dates: 04/03/2016 to 15/05/2016
EMA/CVMP/ADVENT/226871/2015